Efficacy of parecoxib for the prevention of catheter-related bladder discomfort after transurethral resection of bladder

Abstract

Objective The aim of this study was to assess the prevention profiles of parecoxib on catheter-related bladder discomfort (CRBD) after transurethral resection of bladder tumor(TURBT). Methods Fifty-six male adult patients undergoing transurethral resection of bladder tumor were enrolled. Induction and maintenance of anesthesia were standardized. Patients were randomly divided into two groups according to the random number table method that received either intravenous 0.9% NaCl solution[control group (group C)] or parecoxib (40 mg) (group P) at 10 min before the end of the operation. The incidence and severity of CRBD, postoperative pain, Ramsay scores, patient satisfaction, postoperative additional drugs and adverse effects were assessed at 5 min (T1), 1 h (T2), 6 h (T3) and 12 h (T4) after administration of the parecoxib by another observer who does not know research grouping situation. Results The incidence of CRBD in group P at T1, T2 and T3 was significantly lower than that in group C (89.3% vs 46.4%, 89.3% vs 35.7%, 67.9% vs 39.3%)(P 0.05). Conclusions Not only can a single intravenous injection of parecoxib 40 mg at the end of surgery effectively reduce the incidence and severity of postoperative CRBD in patients with TURBT, but also has certain analgesic effect without causing serious adverse reaction. Key words: Parecoxib; Catheter-related bladder discomfort; Transurethral resection of bladder tumor